Louise B. Callesen

Palle Juul Jensens Blvd. 99
Aarhus N, 8200, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Systematic review and meta-analysis of studies assessing circulating tumor DNA kinetics in metastatic colorectal cancer.

Systematic review and meta-analysis of studies assessing circulating tumor DNA kinetics in metastatic colorectal cancer.

Journal: ESMO gastrointestinal oncology

Published: March 11, 2026

Prognostic significance of circulating tumor DNA as a baseline or dynamic factor in advanced NSCLC without oncogenic drivers: A systematic review and meta-analysis.

Prognostic significance of circulating tumor DNA as a baseline or dynamic factor in advanced NSCLC without oncogenic drivers: A systematic review and meta-analysis.

Journal: Critical reviews in oncology/hematology

Published: November 27, 2025

Circulating tumour DNA (ctDNA) as a predictor of progression-free and overall survival in non-resectable pancreatic cancer: a systematic review and meta-analysis.

Circulating tumour DNA (ctDNA) as a predictor of progression-free and overall survival in non-resectable pancreatic cancer: a systematic review and meta-analysis.

Journal: The journal of liquid biopsy

Published: September 20, 2025

ctDNA-guided adjuvant treatment after radical-intent treatment of metastatic spread from colorectal cancer-the first interim results from the OPTIMISE study.

ctDNA-guided adjuvant treatment after radical-intent treatment of metastatic spread from colorectal cancer-the first interim results from the OPTIMISE study.

Journal: Acta oncologica (Stockholm, Sweden)

Published: September 22, 2023

Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group.

Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group.

Journal: Scientific reports

Published: July 12, 2023

Time for a lead-time definition? Author response to 'Why the length of recurrence free survival or "lead-times" can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis'.

Time for a lead-time definition? Author response to 'Why the length of recurrence free survival or "lead-times" can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis'.

Journal: Therapeutic advances in medical oncology

Published: March 23, 2023

The Importance of Feasibility Assessment in the Design of ctDNA Guided Trials - Results From the OPTIPAL II Study.

The Importance of Feasibility Assessment in the Design of ctDNA Guided Trials - Results From the OPTIPAL II Study.

Journal: Clinical colorectal cancer

Published: December 22, 2022

OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol.

OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol.

Journal: Acta oncologica (Stockholm, Sweden)

Published: September 12, 2022

Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis.

Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis.

Journal: Therapeutic advances in medical oncology

Published: August 31, 2022

Circulating cell-free DNA as predictor of pathological complete response in locally advanced rectal cancer patients undergoing preoperative chemoradiotherapy.

Circulating cell-free DNA as predictor of pathological complete response in locally advanced rectal cancer patients undergoing preoperative chemoradiotherapy.

Journal: Clinical and translational radiation oncology

Published: February 02, 2022

Reporting on circulating tumor DNA monitoring in metastatic cancer-From clinical validity to clinical utility.

Reporting on circulating tumor DNA monitoring in metastatic cancer-From clinical validity to clinical utility.

Journal: Cancer

Published: December 14, 2021

Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis.

Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis.

Journal: British journal of cancer

Published: December 03, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026